香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 甲磺酸阿美替尼片 單藥治療於歐盟獲批上市 翰森製藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董 事會」）欣然宣佈，於二零二六年二月十二日，本集團創新藥甲磺酸阿美替尼片 （中國商品名：阿美樂®，海外商品名：Aumseqa®）單藥治療已於歐盟獲批上市， 用於：(i)具有表皮生長因子受體（「EGFR」）外顯子19缺失或外顯子21(L858R) 置換突變的晚期非小細胞肺癌（「NSCLC」）成人患者的一線治療，以及(ii)晚期 EGFR T790M突變陽性NSCLC成人患者的治療。此次批准由歐盟委員會(EC)基於 歐洲藥品管理局(EMA)人用藥品委員會(CHMP)的積極意見作出。 關於甲磺酸阿美替尼片 甲磺酸阿美替尼片是中國首個原研三代EGFR-TKI創新藥，此前已獲國家藥 品監督 ...

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has shown significant movement, with a 53% increase in related warrants, indicating strong market interest and potential for further price challenges in the near future [1][7]. Company Analysis - CSPC Pharmaceutical's latest stock price is 9.96 HKD, with a slight increase of 1.53% and a trading volume of 6.79 billion HKD. The current support levels are at 8.90 HKD and 8.18 HKD, while resistance levels are at 10.32 HKD and 11.00 HKD, suggesting a 51% probability of upward movement [1]. - The technical indicators for CSPC show an RSI of 76, indicating an overbought condition, and both the Williams and stochastic indicators are signaling a sell [2]. - The stock has rebounded to 10 HKD after a previous high of 11.49 HKD in August-September of the previous year, suggesting potential for future price challenges [4]. Industry Insights - The application of AI in the biopharmaceutical sector is highlighted as a key driver for innovation and profitability, with CSPC and similar companies benefiting from this trend [4]. - The biopharmaceutical sector, including companies like WuXi Biologics (2269), is experiencing high market expectations for profitability, with stock prices reflecting this optimism [5][6]. - The overall sentiment in the biopharmaceutical sector is strong, but technical indicators suggest that many stocks, including CSPC, are facing overbought conditions, indicating a potential for price corrections [6][7]. Warrants and Leverage - The warrants related to CSPC have shown significant leverage effects, with some warrants increasing by as much as 53% in response to the stock's movements. The warrants' performance indicates a strong correlation with the underlying stock [7][9]. - Specific warrants, such as the HSBC call warrant (17233), have a leverage of 7.5 times and are positioned close to the current stock price, enhancing their potential for value appreciation [9][10]. - The recommended warrants for cautious investors include the HSBC call warrant (17233) and the Bank of China bull warrant (65938), both of which offer favorable leverage and lower premium levels [9][11].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 自願性公告－ 拓益®新增適應症和君適達®納入國家醫保目錄 本公告由上海君實生物醫藥科技股份有限公司（「本公司」）自願作出。請亦參見本 公司於2025年12月7日刊發的海外監管公告。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司產品特瑞普利單抗注射液 （商品名：拓益®，產品代號：JS001）2項新增適應症、昂戈瑞西單抗注射液（商 品名：君適達®，產品代號：JS002）成功納入《國家基本醫療保險、生育保險和工 傷保險藥品目錄（2025年）》（「國家醫保目錄」）乙類範圍。新版國家醫保目錄將於 2026年1月1日起正式實施。 截至本公告日期，本公司4款商業化產品拓益®、阿達木單抗注射液（商品名：君 邁康®，產品代號：UBP1 ...

Core Viewpoint - Wanbangde demonstrates strong resilience in a challenging pharmaceutical manufacturing environment, achieving a revenue of 579 million yuan and a net profit of 13.46 million yuan in the first half of 2025 [1] Revenue Composition - The "Professional Equipment Manufacturing and Services" segment surpassed "Pharmaceutical Manufacturing" for the first time, contributing 41.63% to the company's revenue, primarily due to the impact of national procurement policies [1] R&D Investment - The company increased its R&D investment to 31.14 million yuan, a year-on-year growth of 13.48%, focusing on the development of traditional Chinese medicine, chemical drugs, and raw materials [2] Transition to Innovative Drugs - Wanbangde is shifting from generic drugs to innovative drugs, with seven ongoing innovative drug projects, including "WP103" and "WP107," which have received clinical trial approval in the U.S. [3][4] Addressing Disease Trends - The company is developing new drugs targeting obesity and Alzheimer's disease, with significant progress in clinical trials and patent approvals for innovative combinations [4] Strengthening R&D Capabilities - Wanbangde is enhancing its R&D capabilities by attracting high-end talent and building a competitive technology development platform, while also exploring AI applications in drug development [5] International Expansion - The company is actively pursuing international markets, with its South African operations generating 172 million yuan in revenue, a 1.45% increase, and a net profit of 6.21 million yuan, up 884.25% [6] Global Market Recognition - Wanbangde's medical device products have received multiple international certifications, including FDA and CE approvals, and the company has significant production capacity for various medical devices [6] Strategic Development - The company plans to continue its focus on the pharmaceutical manufacturing and medical device sectors, integrating its operations with the "Belt and Road" initiative to enhance long-term growth [7]